Candida glabrata ( Nakaseomyces glabrata ): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List
Medical Mycology · 27.06.2024 · 62 (6)
DOI: 10.1093/mmy/myae041 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medical Mycology, online erschienen am 27.06.2024. Verfasst von Justin Beardsley und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Infectious Diseases Institute, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Candida glabrata, Drug Resistance, Fungal, Antifungal Agents, World Health Organization. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: World Health Organization, Ministry of Education and Science.
Abstract (Originalsprache)
Recognising the growing global burden of fungal infections, the World Health Organization (WHO) established an advisory group consisting of experts in fungal diseases to develop a Fungal Priority Pathogen List. Pathogens were ranked based on their research and development needs and perceived public health importance using a series of global surveys and pathogen characteristics derived from systematic reviews. This systematic review evaluates the features and global impact of invasive disease caused by Candida glabrata (Nakaseomyces glabrata). PubMed and Web of Science were searched for studies reporting on mortality, morbidity (hospitalization and disability), drug resistance (including isolates from sterile and non-sterile sites, since these reflect the same organisms causing invasive infections), preventability, yearly incidence, diagnostics, treatability, and distribution/emergence in the last 10 years. Candida glabrata (N. glabrata) causes difficult-to-treat invasive infections, particularly in patients with underlying conditions such as immunodeficiency, diabetes, or those who have received broad-spectrum antibiotics or chemotherapy. Beyond standard infection prevention and control measures, no specific preventative measures have been described. We found that infection is associated with high mortality rates and that there is a lack of data on complications and sequelae. Resistance to azoles is common and well described in echinocandins—in both cases, the resistance rates are increasing. Candida glabrata remains mostly susceptible to amphotericin and flucytosine. However, the incidence of the disease is increasing, both at the population level and as a proportion of all invasive yeast infections, and the increases appear related to the use of antifungal agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sydney Infectious Diseases Institute, The University of Sydney, Sydney, Australia.
- Westmead Institute for Medical Research, Sydney, Australia.
- School of Pharmacy, University of Sydney, Sydney, Australia.
- Department of Pharmacy, Westmead Hospital, Sydney, Australia.
- National Mycology Reference Centre, SA Pathology, Adelaide, Australia.
- Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Justin Beardsley, Aiken Dao, Sarah Kidd, Ana Alastruey-Izquierdo, Tania C Sorrell, Arunaloke Chakrabarti, Jan-Willem Alffenaar
Förderung
- World Health Organization
- Ministry of Education and Science
Zitieren
APA
Beardsley, J., Kim, H. Y., Dao, A., Kidd, S., Alastruey-Izquierdo, A., Sorrell, T. C., Tacconelli, E., Chakrabarti, A., Harrison, T. S., Bongomin, F., Gigante, V., Galas, M., Siswanto, S., Dagne, D. A., Roitberg, F., Sati, H., Morrissey, C. O., & Alffenaar, J. W. (2024). Candida glabrata ( Nakaseomyces glabrata ): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List. Medical Mycology, 62(6). https://doi.org/10.1093/mmy/myae041
Vancouver
Beardsley J, Kim HY, Dao A, Kidd S, Alastruey-Izquierdo A, Sorrell TC, et al. Candida glabrata ( Nakaseomyces glabrata ): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List. Medical Mycology. 2024;62(6). doi:10.1093/mmy/myae041
BibTeX
@article{Beardsley2024,
author = {Beardsley, Justin and Kim, Hannah Yejin and Dao, Aiken and Kidd, Sarah and Alastruey-Izquierdo, Ana and Sorrell, Tania C and Tacconelli, Evelina and Chakrabarti, Arunaloke and Harrison, Thomas S and Bongomin, Felix and Gigante, Valeria and Galas, Marcelo and Siswanto, Siswanto and Dagne, Daniel Argaw and Roitberg, Felipe and Sati, Hatim and Morrissey, C Orla and Alffenaar, Jan-Willem},
title = {Candida glabrata ( Nakaseomyces glabrata ): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List},
journal = {Medical Mycology},
year = {2024},
volume = {62},
number = {6},
doi = {10.1093/mmy/myae041}
}
EUVIMED